Point Of Care Lipid Test Market Growth & Trends:
The global point of care lipid test market is anticipated to reach USD 1.1 billion by 2030 and is anticipated to expand at a CAGR of 6.5% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and kidney disorders is a key driver contributing to the market growth, as these conditions often necessitate frequent lipid monitoring for effective management. Cardiovascular complications remain a major concern for patients with kidney disease, where factors such as elevated lipid levels and systemic inflammation increase risks.
Furthermore, this trend aligns with the broader emphasis on preventive healthcare, where early detection of lipid imbalances helps mitigate long-term health risks. Portable testing devices enable real-time results at clinics, hospitals, or homes, streamlining patient care and empowering individuals to manage their health proactively. The integration of these tools with digital platforms supports remote monitoring, a practice that gained momentum during the pandemic and remains relevant for reducing unnecessary clinical visits.
Point Of Care Lipid Test Market Report Highlights:
- Consumables dominated the product segment and accounted for the largest revenue share of 61.9% in 2024. This is attributed to the need for disposable and single-use consumables for rapid, user-friendly testing procedures.
- Instruments are expected to grow at a CAGR of 6.6% over the forecast period, owing to contemporary analyzers' improved accuracy, mobility, and connectivity features, which make them perfect for decentralized situations.
- The hyperlipidemia held the largest revenue share of 46.9% in 2024, primarily driven by the rising necessity for quick, effective management of chronic diseases such as diabetes and cardiovascular disease.
- Hypertriglyceridemia is expected to grow at a CAGR of 7.0% over the forecast period, owing to the rapid developments in testing technologies that improve speed and accessibility.
- Lipid and lipoprotein disorders dominated the market, with the largest revenue share of 38.7% in 2024. Atherosclerosis is expected to grow at a significant CAGR from 2025 to 2030.
- The hospitals segment held the dominant position in the market and accounted for the largest revenue share, 32.2%, in 2024. Hospitals need quick, precise lipid testing to allow appropriate diagnosis and management of chronic situations, enhancing patient outcomes.
- North America dominated the global point-of-care lipid test market and accounted for the largest revenue share of 43.6% in 2024, primarily due to the incorporation of point-of-care testing with telehealth platforms, which improves user-friendliness and patient engagement.